MCID: BRS049
MIFTS: 41

Breast Carcinoma in Situ malady

Genetic diseases, Cancer diseases, Rare diseases, Reproductive diseases categories

Aliases & Classifications for Breast Carcinoma in Situ

About this section

Aliases & Descriptions for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 10
Non-Infiltrating Carcinoma of Breast 10
 
Carcinoma in Situ of Breast 10
Stage 0 Breast Carcinoma 65


Classifications:



External Ids:

Disease Ontology10 DOID:8791
ICD9CM29 233.0
NCIt42 C3641
ICD1027 D05

Summaries for Breast Carcinoma in Situ

About this section
MalaCards based summary: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast cancer and li-fraumeni syndrome. An important gene associated with Breast Carcinoma in Situ is TP53 (Tumor Protein P53), and among its related pathways are Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics and BRCA1 Pathway. Affiliated tissues include breast and testes, and related mouse phenotypes are renal/urinary system and adipose tissue.

Related Diseases for Breast Carcinoma in Situ

About this section

Diseases in the Breast Cancer family:

Sporadic Breast Cancer Inflammatory Breast Carcinoma
Breast Benign Neoplasm breast carcinoma in situ
Familial Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Chek2-Related Susceptibility to Breast Cancer
Rad51-Related Susceptibility to Breast Cancer

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 189)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer28.1BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1
2li-fraumeni syndrome10.5
3adenocarcinoma in situ10.5
4ductal carcinoma in situ10.5
5breast medullary carcinoma10.5
6lobular neoplasia10.5
7adrenal medulla carcinoma10.5
8skin carcinoma in situ10.5
9female breast carcinoma10.5
10breast adenocarcinoma10.5
11breast disease10.5
12breast ductal carcinoma10.5
13in situ carcinoma10.5
14adenocarcinoma10.4
15congenital pulmonary veins atresia or stenosis10.4BRCA1, BRCA2
16bronchiolitis obliterans10.3BRCA1, BRCA2
17breast cancer, childhood10.3BRCA1, BRCA2
18skin disease10.3
19brca2 hereditary breast and ovarian cancer syndrome10.3BRCA1, BRCA2
20pancreatic islet cell tumors10.3BRCA1, BRCA2, TP53
21ciliopathy10.3BRCA1, BRCA2, TP53
22mutiple parosteal osteochondromatous proliferations10.3BRCA1, BRCA2, TP53
23spondyloepimetaphyseal dysplasia, sponastrime type10.3BRCA1, BRCA2, TP53
24bleeding disorder, platelet-type, 1310.3BRCA2, CYP19A1, TP53
25alopecia, androgenetic, 110.2CYP19A1, SRD5A1, STS
26poland syndrome10.2
27chordoma10.2KRT19, MET, TP53
28amyloid tumor10.2BRCA1, BRCA2, MET, TP53
29animal phobia10.2BRCA1, BRCA2, PGR
30breast sarcoma10.2ERBB2, TP53
31hemophilia b10.2
32hemophilia a10.2
33skin conditions10.2
34coagulation protein disease10.2
35estrogen-receptor positive breast cancer10.2
36oral cavity carcinoma in situ10.2
37breast apocrine carcinoma in situ10.2
38comedo carcinoma10.2
39collecting duct carcinoma10.2
40delta chain disease10.2
41nipple duct carcinoma10.2
42blood coagulation disease10.2
43blood protein disease10.2
44bone cancer10.2
45oral cavity cancer10.2
46ovarian cancer10.2
47skin benign neoplasm10.2
48factor v leiden thrombophilia10.2
49familial breast cancer10.2
50oral cancer10.2

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Symptoms for Breast Carcinoma in Situ

About this section

Drugs & Therapeutics for Breast Carcinoma in Situ

About this section

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 132)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluorouracilapprovedPhase 3, Phase 2193751-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
2
MethotrexateapprovedPhase 313871959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
Methopterin
Methotextrate
 
Methotrate
Methotrexat
Methotrexate
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metoject
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Otrexup
Rasuvo
Rheumatrex
Rheumatrex Dose Pack
Trexall
3
EpirubicinapprovedPhase 3, Phase 234356420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
4
Cyclophosphamideapproved, investigationalPhase 3, Phase 2252550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
5
Raloxifeneapproved, investigationalPhase 36284449-90-15035
Synonyms:
(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone
82640-04-8 (hydrochloride)
84449-90-1
AC1L1JGT
BIDD:ER0216
BIDD:GT0795
BPBio1_000995
BSPBio_000903
C07228
C28H27NO4S
CAS-82640-04-8
CCRIS 7129
CHEBI:45355
CHEBI:8772
CHEMBL81
CID5035
D08465
DB00481
Eviden
Eviden (TN)
Evista
HMS2089F06
HSDB 7460
KBio2_002361
KBio2_004929
KBio2_007497
KBio3_002840
KBioGR_002361
KBioSS_002364
Keoxifene
LS-177821
LY 139481
LY-139481
Lopac-R-1402
 
Lopac0_001051
MolPort-003-850-106
NCGC00015889-01
NCGC00015889-02
NCGC00015889-07
NCGC00092353-02
NSC747974
Prestwick0_000862
Prestwick1_000862
Prestwick2_000862
Prestwick3_000862
RAL
Raloxifene
Raloxifene (INN)
Raloxifene Hcl
Raloxifene Hydrochloride
Raloxifene [INN:BAN]
Raloxifeno
Raloxifeno [Spanish]
Raloxifenum
Raloxifenum [Latin]
Raxeto
Raxeto (TN)
SMP2_000095
SPBio_002824
UNII-YX9162EO3I
VU0155042-3
[2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
cMAP_000032
nchembio.140-comp6
nchembio.76-comp4
raloxifene
6
Letrozoleapproved, investigationalPhase 3, Phase 2, Phase 1326112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
7
CarboplatinapprovedPhase 3, Phase 2181241575-94-410339178, 498142, 38904, 38904, 498142
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
8
ProgesteroneapprovedPhase 3, Phase 2, Phase 047357-83-05994
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17a-Progesterone
17alpha-Progesterone
17alpha-progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
46665_FLUKA
46665_RIEDEL
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC-700
AC1L1LKF
AI3-51682
Agolutin
Akrolutin
BB_NC-0185
BHR-100
BIDD:ER0547
BIDD:PXR0094
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
Bio-luton
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
CPD000058345
Colprosterone
Corlutin
Corlutina
Corluvite
Corporin
Corpus Luteum Hormone
Corpus luteum hormone
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
DR-2011
Delalutin
Delta(4)-pregnene-3,20-dione
Duraprogen
EINECS 200-350-6
ETI-411
EU-0100895
Endometrin
Estima
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
HSDB 3389
Hormoflaveine
Hormoluton
Hydroxyprogesterone Caproate
Hydroxyprogesterone Caproic acid
LMST02030159
LS-234
Lingusorbs
Lipo-Lutin
Lipolutin
Lopac0_000895
Lucorteum
Lucorteum Sol
Lucorteum sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin M
Lutocyclin
Lutocyclin M
 
Lutocyclin m
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MPA
Membrettes
Methylpregnone
Micronized Progesterone
MolPort-001-794-643
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
NCI60_042166
NSC 64377
NSC 9704
NSC-9704
NSC64377
NSC9704
Nalutron
Natural Progesterone
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
PROGESTERONE
Percutacrine
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Prestwick_411
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, water-soluble
Progesterone-Water Soluble
Progesterone: HBC complex
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Progestérone
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
SR-01000000088
SR-01000000088-5
Spectrum5_002053
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
beta-Progesterone
bmse000482
component of Cyclogesterin
corpus luteum hormone
delta(4)-Pregnene-3,20-dione
delta(Sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta4-Pregnene-3,20-dione
luteohormone
nchembio.2007.53-comp14
9
Anastrozoleapproved, investigationalPhase 3, Phase 2252120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
10
Trastuzumabapproved, investigationalPhase 3, Phase 2, Phase 1688180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
11
Doxorubicinapproved, investigationalPhase 3, Phase 2, Phase 1152523214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
12
Fentanylapproved, illicit, investigationalPhase 3649437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
13
PaclitaxelapprovedPhase 3, Phase 2250533069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
14
Estradiolapproved, investigationalPhase 3, Phase 2105750-28-25757, 53477783
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
1,3,5[10]-Estratriene-3,17beta-diol 3-sulfate
1,3,5[10]-Estratriene-3,17beta-diol 3-sulphate
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta-Estradiol
17-.BETA.-Estradiol
17-E
17-beta
17-beta-OH-estradiol
17-beta-estradiol
17.beta.-Estradiol
17.beta.-Oestradiol
17E
17b-Estradiol
17b-Oestradiol
17beta Oestradiol
17beta oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17beta-Estradiol
17beta-Oestradiol
1jgl
1qkt
1qku
2d06
3,17-Epidihydroxyestratriene
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulfate
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulphate
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
B-Estradiol
BEDOs
BIDD:ER0125
BIDD:PXR0065
BPBio1_000532
BSPBio_000482
BSPBio_001065
Bardiol
Benzhormovarine
Beta-estradiol
Bio-0812
Bio-E-Gel
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
CMC_11154
CPD-352
CPD000059126
Climaderm
Climara
Climara (TN)
Climara Forte
Compudose
Compudose 200
Compudose 365
Corpagen
D-3,17beta-Estradiol
D-Estradiol
D-Oestradiol
D00105
DB00783
Depo-estradiol
Dermestril
Destradiol
Dihydro-Theelin
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
Dihydrotheelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
EU-0100503
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
Estradiol
Estradiol Transdermal System
Estradiol Valerate
Estradiol [USAN:INN]
Estradiol acetate
Estradiol benzoate
Estradiol cypionate
Estradiol valerate
Estradiol-17 beta
Estradiol-17-beta
Estradiol-17.beta.
Estradiol-17beta
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
Estreva
Estrifam
Estring
Estring (TN)
Estring Vaginal Ring
Estring vaginal ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
 
Estrofem Forte
Estrogel
Estrogel (TN)
Estrogel HBF
Estrovite
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femring
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
GynPolar
Gynergon
Gynestrel
Gynodiol
Gynoestryl
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
LMST02010001
LS-137
Lamdiol
Lio-Oid
Lopac0_000503
MLS000069494
MLS000758312
MLS001076331
Macrodiol
Macrol
Menest
Menorest
Menostar
Microdiol
Minivelle
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
NSC-9895
NSC9895
Nordicol
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17-beta
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Prestwick_207
Primofol
Profoliol
Profoliol B
Progynon
Progynon DH
Progynon-DH
S-21400
S1709_Selleck
SAM001247032
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Sandrena 1
Sandrena Gel
Sisare Gel
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
VIVELLE-DOT
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
Vivelle Dot
Vivelle-dot
Zerella
Zesteem
Zesteen
Zumenon
[2,4,6,7-3H]-E2
[3H]-estradiol
[3H]]estradiol
b-Estradiol
beta-Estradiol
beta-Estradiol 3-sulfate
beta-Estradiol 3-sulphate
bmse000642
cMAP_000005
cis-Estradiol
cis-Oestradiol
component of Menrium
delta-Estradiol
delta-Oestradiol
estradiol
estradiol-17beta
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
progynon
15
Medroxyprogesterone Acetateapproved, investigationalPhase 313171-58-9
Synonyms:
(6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17-Acetoxy-6alpha-methylprogesterone
17-Acetoxy-6α-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone acetate
17α-hydroxy-6α-methylprogesterone acetate
6-alpha-Methyl-17-alpha-acetoxyprogesterone
6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate
6alpha-Methyl-17-acetoxy progesterone
6alpha-Methyl-17alpha-hydroxyprogesterone acetate
6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate
6α-Methyl-17-acetoxy progesterone
 
6α-Methyl-17α-hydroxyprogesterone acetate
Depo-provera
Depo-subq Provera
MPA
Makena
Medroxyacetate progesterone
Medroxyprogesterone 17-acetate
Medroxyprogesterone Acetate
Medroxyprogesterone acetate
Methylacetoxyprogesterone
Metigestrona
Provera
16
TamoxifenapprovedPhase 3, Phase 2, Phase 134110540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Soltamox
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
17
NorethindroneapprovedPhase 37968-22-46230
Synonyms:
(17-alpha)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one
(17alpha)-17-Ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one
17-Ethinyl-19-nor-testosterone
17-Ethinyl-19-nortestosterone
17-Ethynyl-17-hydroxyestr-4-en-3-one
17-Ethynyl-17-hydroxyestr-4-en-3-one (ACD/Name 4.0)
17-Ethynyl-17beta-hydroxyestr-4-en-3-one
17-Ethynyl-19-Nortestosterone
17-Hydroxy-(17alpha)-19-Norpregn-4-en-20-yn-3-one
17-Hydroxy-17-alpha-19-Norpregn-4-en-20-yn-3-one
17-Hydroxy-17-alpha-19-norpregn-4-en-20-yn-3-one
17-Hydroxy-19-Nor-17alpha-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-one
17-alpha-Ethynyl-17-beta-hydroxy-4-estren-3-one
17-alpha-Ethynyl-17-hydroxy-4-estren-3-one
17-alpha-Ethynyl-19-norandrost-4-en-17-beta-ol-3-one
17-alpha-Ethynyl-19-nortestosterone
17-alpha-Ethynyl-4-estren-17-ol-3-one
17-beta-Hydroxy-19-norpregn-4-en-20-yn-3-one
17-ethynyl-17beta-hydroxyestr-4-en-3-one
17.alpha.-Ethinyl-19-nortestosterone
17.alpha.-Ethynyl-19-nortestosterone
17.alpha.-Ethynyl-4-estren-17-ol-3-one
17alpha-Ethinyl-17alpha-Ethinyl-19-nortestosterone
17alpha-Ethinyl-19-Nortestosterone
17alpha-Ethinyl-19-nortestosterone
17alpha-Ethinylestra-4-en-17beta-ol-3-one
17alpha-Ethynyl-17-hydroxy-4-estren-3-one
17alpha-Ethynyl-17-hydroxyest-4-en-3-one
17alpha-Ethynyl-17beta-hydroxy-19-norandrost-4-en-3-one
17alpha-Ethynyl-17beta-hydroxyestr-4-en-3-one
17alpha-Ethynyl-19-nor-4-androsten-17beta-ol-3-one
17alpha-Ethynyl-19-norandrost-4-en-17beta-ol-3-one
17alpha-Ethynyl-19-nortestosterone
17alpha-Ethynyl-3-oxo-4-estren-17beta-ol
17alpha-Ethynyl-4-estren-17-ol-3-one
17alpha-ethynyl-17-hydroxy-Estr-4-en-3-one
17alpha-ethynyl-17beta-hydroxy-19-Norandrost-4-en-3-one
17alpha-pregn-4-en-20-yn-3-one
17beta-Hydroxy-17alpha-ethynylestr-4-en-3-one
17beta-Hydroxy-19-norpregn-4-en-20-yn-3-one
17α-ethinyl-19-nortestosterone
19-Nor-17-alpha-ethynyl-17-beta-hydroxy-4-androsten-3-one
19-Nor-17-alpha-ethynylandrosten-17-beta-ol-3-one
19-Nor-17-alpha-ethynyltestosterone
19-Nor-17-ethinyl testosterone
19-Nor-17-ethinyltestosterone
19-Nor-17.alpha.-ethynyltestosterone
19-Nor-17alpa-ethynyltestosterone
19-Nor-17alpha-Ethynyl-17beta-hydroxy-4-androsten-3-one
19-Nor-17alpha-Ethynylandrosten-17beta-ol-3-one
19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one
19-Nor-17alpha-ethynylandrosten-17beta-ol-3-one
19-Nor-17alpha-ethynyltestosterone
19-Nor-ethindrone
19-Nor-ethinyl--4,5-testosterone
19-Norethindrone
19-Norethinyltestosterone
19-Norethisterone
19-nor-17α-ethynyltestosterone
4-Estren-17alpha-ethynyl-17beta-ol-3-one
46525_FLUKA
46525_RIEDEL
68-22-4
A3564/0151191
AC-11100
AC1L1IDS
AC1L1M2R
AC1NWAOX
AC1O5EOU
AC1Q6OG5
AI3-26422
AKOS004119895
AR-1C1071
ARONIS24281
Activella
Anhydrohydroxynorprogesterone
Anovulatorio
Anovule
Aygestin
BB_NC-0600
BPBio1_000074
BRD-A39415247-001-02-1
BRD-K92073408-001-03-3
BRN 1915671
BSPBio_000066
BSPBio_002101
Brevicon
Brevinor
Brevinor 21
Brevinor 28
Brevinor-1 21
Brevinor-1 28
C05028
CCRIS 484
CHEBI:7627
CHEMBL1162
CID4536
CID5702093
CID6230
CID6432649
CPD000499579
Camila
Camila (TN)
Ciclovulan
Conceplan
Conludaf
Conludag
D00182
DB00717
Deblitane
Demulen
DivK1c_000553
EINECS 200-681-6
ENT
Errin
Estrinor
Ethinyl-19-nortestosterone
Ethinylnortestosterone
Ethynylmortestosterone
Ethynylnortestosterone
Gencept
Genora
Gestest
HMS1568D08
HMS1920B10
HMS2090D21
HMS2091J10
HMS501L15
HSDB 3370
Heather
I06-0104
IDI1_000553
Jencycla
Jenest
Jenest-28
 
Jolivette
KBio1_000553
KBio2_001491
KBio2_004059
KBio2_006627
KBio3_001601
KBioGR_000637
KBioSS_001491
LMST02030097
LS-97425
Loestrin
Lyza
MLS001076679
MLS001163874
MLS001304093
Menzol
Microneth
Micronett
Micronor
Micronor (TN)
Micronovum
Milli
Mini-PE
Mini-Pe
Mini-pill
Minovlar
MolPort-002-507-131
MolPort-002-509-542
MolPort-002-728-977
MolPort-003-861-444
N.E.E
N.E.E.
N0449
N4128_SIGMA
NCGC00178820-01
NCGC00179669-01
NET
NINDS_000553
NSC-9564
NSC9564
Nelova
Nodiol
Nor Qd
Nor-Q.D
Nor-Q.D.
Nor-QD
Nora Be
Nora-BE
Noraethisteronum
Noralutin
Norcept
Norcept-E
Norcolut
Norcolute
Noresthisterone
Norethadrone
Norethin
Norethin 1/35 E
Norethin 1/50 M
Norethindirone
Norethindrone
Norethindrone (USP)
Norethindrone Acetate
Norethindrone Norethisterone
Norethindrone [USAN]
Norethisteron
Norethisterone
Norethisterone (JP15)
Norethisterone [Progestins]
Norethisteronum
Norethisteronum [INN-Latin]
Norethyndron
Norethynodron
Norethynodrone
Noretisterona
Noretisterona [INN-Spanish]
Noretisterone
Noretisterone [DCIT]
Norfor
Norgestin
Noriday
Noriday 28
Norlutate
Norluten
Norlutin
Norluton
Norlyroc
Normapause
Norpregneninlone
Norpregneninolone
Norpregneninotone
Oprea1_606355
Orlest
Ortho 1 35
Ortho 7 7 7
Ortho Micronor
Ortho-Novum 1 35
Ortho-Novum 1 50
Ortho-Novum 7 7 7
Ovysmen 0.5 35
Ovysmen 1 35
Prestwick0_000253
Prestwick1_000253
Prestwick2_000253
Prestwick3_000253
Prestwick_646
Primolut N
Primolut-N
Primolut-N (TN)
Proluteasi
SAM002564223
SC 4640
SMR000499579
SMR000718762
SPBio_001052
SPBio_002285
SPECTRUM1500437
ST094767
STK730956
STOCK1N-04274
Sharobel
Spectrum2_001066
Spectrum3_000521
Spectrum4_000079
Spectrum5_001198
Spectrum_001011
Synphase
Synphasic 28
Tri-Norinyl
Triella
Trinovum 21
UNII-T18F433X4S
Utovlan
Utovlar
WLN: L E5 B666 OV MUTJ E FQ F1UU1 -A&F
ZINC03814419
component of Noriday
norethindrone
18
MetforminapprovedPhase 3, Phase 01573657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
19
ado-trastuzumab emtansineapprovedPhase 3571018448-65-1
Synonyms:
Kadcyla
 
Trastuzumab-DM1
trastuzumab emtansine
trastuzumab-MCC-DM1
20
Exemestaneapproved, investigationalPhase 3, Phase 2184107868-30-460198
Synonyms:
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
107868-30-4
6-Methylenandrosta-1,4-diene-3,17-dione
6-Methyleneandrosta-1,4-diene-3,17-dione
6-methylideneandrosta-1,4-diene-3,17-dione
AC-2171
AC1L1SRB
AC1Q6AAZ
Ambap107868-30-4
Aromasil
Aromasin
Aromasin (TN)
Aromasin, Exemestane
Aromasine
C056516
C08162
CHEBI:4953
CHEMBL1200374
CID60198
CPD000466314
Curator_000009
D00963
DB00990
EXE
EXEMESTANE
 
Exemestance
Exemestane
Exemestane (JAN/USP/INN)
Exemestane [USAN:INN:BAN]
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
FCE-24304
Fce 24304
HMS2051J04
HSDB 7463
LS-19329
MLS000759419
MLS001424062
MolPort-003-847-343
NSC713563
Nikidess
PNU-155971
Pfizer brand of exemestane
S1196_Selleck
S1196_Sellek
SAM001246574
SMR000466314
UNII-NY22HMQ4BX
ZINC03973334
exemestane
21
PertuzumabapprovedPhase 3100145040-37-5, 380610-27-52540
Synonyms:
2C4 Antibody
380610-27-5
D05446
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MOAB2C4
Monoclonal Antibody 2C4
 
Omnitarg
Perjeta
Pertuzumab
Pertuzumab (USAN/INN)
Pertuzumab (genetical recombination)
Pertuzumab (genetical recombination) (JAN)
pertuzumab
rhuMAb 2C4
rhuMAb-2C4
22
Folic Acidapproved, nutraceuticalPhase 3285159-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
23
Cholecalciferolapproved, nutraceuticalPhase 3, Phase 275567-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7e)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7e)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
 
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
calciol
cholecalciferol
delta-D
vitamin d-3
24
DoxilApproved June 1999Phase 3, Phase 2, Phase 1152531703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
25
Lapatinibapproved, investigational, Approved March 2007Phase 3, Phase 2, Phase 1292231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
26
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 1, Phase 21792114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
27Estradiol valeratePhase 3, Phase 21057979-32-8
28Polyestradiol phosphatePhase 3, Phase 21057
29pancreatic polypeptidePhase 320
30Mometasone furoatePhase 314083919-23-7
31Norethindrone acetatePhase 379
32Estradiol 3-benzoatePhase 3, Phase 21057
33
MedroxyprogesteronePhase 3131520-85-410631
Synonyms:
(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
(6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione
17 alpha Hydroxy 6 alpha Methylprogesterone
17 alpha-Hydroxy-6 alpha-Methylprogesterone
17-Hydroxy-6.alpha.-methylprogesterone
17-Hydroxy-6a-methylprogesterone
17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6alpha-methylprogesterone
17.alpha.-Hydroxy-6.alpha.-methylprogesterone
17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione
17alpha-Hydroxy-6alpha-methylprogesterone
4-08-00-02211 (Beilstein Handbook Reference)
46411_FLUKA
46411_RIEDEL
520-85-4
6-Dihydromegestrol
6-alpha-Methyl-17-alpha-hydroxyprogesterone
6.alpha.-Methyl-17.alpha.-hydroxyprogesterone
6alpha-Methyl-17alpha-hydroxyprogesterone
6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione
6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione
AC-14528
AC1L1VM7
Adgyn Medro
Aragest
Aragest 5
Asconale
BRN 2510965
C07119
CBP-1011
CHEBI:6715
CHEMBL1390
CID10631
CPD000058769
Clinofem
Clinovir
Colirest
Cycrin
D008525
D08166
DB00603
DMPA
Depo-Clinovir
Depo-Prodasone
Depo-Progestin
Depo-Promone
Depo-Provera
Depo-Subq Provera 104
Depot-Medroxyprogesterone acetate
EINECS 208-298-6
Farlutal
Farlutal inyectable
Farlutal inyectable (TN)
Farlutin
G-Farlutal
Gestapuran
HMS2052A13
HSDB 3114
Hematrol
Hydroxymethylprogesterone
Hysron
 
Indivina
LMST02030176
LS-118713
Lunelle
Lutopolar
Lutoral
M6013_SIGMA
MAP
MLS000069571
MLS001076098
MPA Gyn 5
Med-Pro
Medroprogesterone Acetate
Medrossiprogesterone
Medrossiprogesterone [DCIT]
Medrossiprogesterone [Dcit]
Medroxiprogesterona
Medroxiprogesterona [INN-Spanish]
Medroxiprogesteronum
Medroxyprogesteron
Medroxyprogesteron acetate
Medroxyprogesterone (INN)
Medroxyprogesterone Acetate
Medroxyprogesterone Strakan Brand
Medroxyprogesterone [INN:BAN]
Medroxyprogesteronum
Medroxyprogesteronum [INN-Latin]
Meprate
Methylhydroxyprogesterone
Metigestrona
MolPort-005-934-866
NCGC00023064-04
NSC 27408
NSC27408
Nadigest
Nidaxin
Novo-Medrone
Oragest
Perlutex
Perlutex Leo
Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)- (9CI)
Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)- (9CI)
Prodasone
Progestalfa
Progevera
Provera
Proverone
Ralovera
Repromap
Repromix
SAM001246906
SMR000058769
ST082267
Sirprogen
Sodelut G
Strakan Brand of Medroxyprogesterone
U 8840
UNII-HSU1C9YRES
Veramix
ZINC05763835
g-Farlutal
medroxyprogesterone
34Vitamin B ComplexPhase 32775
35Estradiol 17 beta-cypionatePhase 3, Phase 21083
36Calcium, DietaryPhase 3, Phase 13529
37Estrogens, Conjugated (USP)Phase 381
38ProgestinsPhase 3, Phase 2408
39taxanePhase 3, Phase 2, Phase 1313
4017-alpha-hydroxy-progesterone caproatePhase 326
41MaytansinePhase 345
4211-hydroxyprogesteronePhase 326
43vitamin dPhase 3, Phase 21463
44CitrateNutraceuticalPhase 3, Phase 2, Phase 1784
45
Citric AcidnutraceuticalPhase 3, Phase 2, Phase 178477-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
46ColaNutraceuticalPhase 31690
47FolateNutraceuticalPhase 32851
48Folinic AcidNutraceuticalPhase 32498
49Vitamin B9NutraceuticalPhase 32851
50CalciferolNutraceuticalPhase 3, Phase 21028

Interventional clinical trials:

(show top 50)    (show all 274)
idNameStatusNCT IDPhase
1Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast CancerCompletedNCT00742222Phase 4
2Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®RecruitingNCT01448447Phase 4
3Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT SystemRecruitingNCT01644669Phase 4
4Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment DecisionsCompletedNCT00262899Phase 3
5Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in SituCompletedNCT00438659Phase 3
6S9630, Medroxyprogesterone in Treating Women With Breast CancerCompletedNCT00002920Phase 3
7Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast CancerCompletedNCT00026286Phase 3
8Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast CancerCompletedNCT00003771Phase 3
9Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
10Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast CancerCompletedNCT01112254Phase 3
11Intraoperative Gamma Camera for Breast Cancer SurgeryCompletedNCT00757302Phase 3
12Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenCompletedNCT00003906Phase 3
13Study of Docetaxel in Breast Cancer PatientsCompletedNCT00174707Phase 3
14Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast CancerCompletedNCT00075270Phase 3
15Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By SurgeryCompletedNCT00963729Phase 3
16"The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"CompletedNCT00539474Phase 3
17Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerCompletedNCT00021255Phase 3
18Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast CancerRecruitingNCT01905046Phase 3
19Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerRecruitingNCT01272037Phase 3
20Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in SituRecruitingNCT00907868Phase 3
21Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised StudyRecruitingNCT01509781Phase 3
22Therapeutic Nipple Sparing Mastectomy.RecruitingNCT02311959Phase 3
23A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)RecruitingNCT01772472Phase 3
24Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast CancerRecruitingNCT01608451Phase 3
25Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone LumpectomyActive, not recruitingNCT00769379Phase 3
26Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast CancerActive, not recruitingNCT00103181Phase 3
27Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation TherapyActive, not recruitingNCT00053898Phase 3
28Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In SituActive, not recruitingNCT00072462Phase 3
29Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in SituActive, not recruitingNCT00003857Phase 3
30Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast CancerActive, not recruitingNCT00004205Phase 3
31Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by SurgeryActive, not recruitingNCT01349322Phase 3
32Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 MutationActive, not recruitingNCT00673335Phase 3
33RAPID: Randomized Trial of Accelerated Partial Breast IrradiationActive, not recruitingNCT00282035Phase 3
34Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastActive, not recruitingNCT00470236Phase 3
35APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast CancerActive, not recruitingNCT00402519Phase 3
36Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial NeoplasiaActive, not recruitingNCT01357772Phase 3
37Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing CoordinatorActive, not recruitingNCT00321048Phase 3
38Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast CancerActive, not recruitingNCT00083174Phase 3
39A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive PrimaryActive, not recruitingNCT01966471Phase 3
40Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerActive, not recruitingNCT00878709Phase 3
41A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast CancerActive, not recruitingNCT01358877Phase 3
42Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast CancerActive, not recruitingNCT00073528Phase 3
43Management of Low-risk DCISNot yet recruitingNCT02492607Phase 3
44Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCISWithdrawnNCT00324714Phase 3
454-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in SituCompletedNCT00952731Phase 2
46Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast CancerCompletedNCT00416403Phase 2
47Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast CancerCompletedNCT00054301Phase 2
48Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast CancerCompletedNCT00354640Phase 2
49Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast CancerCompletedNCT00334542Phase 2
50Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast CancerCompletedNCT00244959Phase 2

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

About this section

Anatomical Context for Breast Carcinoma in Situ

About this section

MalaCards organs/tissues related to Breast Carcinoma in Situ:

33
Breast, Testes

Animal Models for Breast Carcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

38 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053678.9BRCA1, ESR1, FGFR1, IL6, MET, TP53
2MP:00053758.7BRCA1, CYP19A1, ESR1, FLT4, IL6, LIF
3MP:00053718.5BRCA1, BRCA2, ERBB2, ESR1, FGFR1, MET
4MP:00053918.3FGFR1, IL6, KDR, LIF, MET, TP53
5MP:00053707.7CYP19A1, ESR1, FLT4, IL6, KDR, LIF
6MP:00053887.7BRCA1, ERBB2, ESR1, IL6, KDR, LIF
7MP:00030127.5ESR1, FGFR1, FLT4, KDR, KRT19, MET
8MP:00020067.3BRCA1, BRCA2, ERBB2, ESR1, IL6, KRT19
9MP:00053976.9BRCA1, BRCA2, CYP19A1, ESR1, IL6, KDR
10MP:00028736.8BRCA1, BRCA2, CYP19A1, ERBB2, FGFR1, FLT4
11MP:00053816.7BRCA1, BRCA2, ERBB2, ESR1, FGFR1, FLT4
12MP:00053866.5BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1
13MP:00053696.5BRCA1, CYP19A1, ERBB2, ESR1, FGFR1, FLT4
14MP:00053876.3BRCA1, BRCA2, CYP19A1, ESR1, FGFR1, FLT4
15MP:00053806.2BRCA1, BRCA2, ERBB2, ESR1, FGFR1, FLT4
16MP:00036316.1BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1
17MP:00053906.1BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1
18MP:00053766.0BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FLT4
19MP:00053785.8BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1
20MP:00053845.8BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1
21MP:00053895.7BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FLT4
22MP:00107715.6BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1
23MP:00053855.6BRCA1, CYP19A1, ERBB2, ESR1, FGFR1, FLT4
24MP:00107685.6BRCA1, BRCA2, ERBB2, ESR1, FGFR1, FLT4
25MP:00053794.8BRCA1, BRCA2, CYP19A1, ERBB2, ESR1, FGFR1

Publications for Breast Carcinoma in Situ

About this section

Articles related to Breast Carcinoma in Situ:

(show all 41)
idTitleAuthorsYear
1
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. (26062614)
2015
2
Usefulness and limitations of E-cadherin and I^-catenin in the classification of breast carcinomas in situ with mixed pattern. (23837653)
2013
3
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. (22595929)
2012
4
Differences in breast carcinoma in situ between menopausal and premenopausal women. (21617240)
2011
5
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. (21149333)
2010
6
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. (20565829)
2010
7
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? (19896281)
2010
8
Prevalence of breast carcinoma in situ in the United States. (19706857)
2009
9
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. (18665169)
2008
10
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). (18317962)
2008
11
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. (17244359)
2007
12
Cigarette smoking and risk of breast carcinoma in situ. (17700252)
2007
13
Oral contraceptive use and risk of breast carcinoma in situ. (18006914)
2007
14
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. (17063272)
2007
15
Quality of life for women diagnosed with breast carcinoma in situ. (17050872)
2006
16
Oral contraceptive use and risk of breast carcinoma in situ (United States). (17006721)
2006
17
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. (15540225)
2005
18
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. (15841074)
2005
19
Impact of reproductive factors and lactation on breast carcinoma in situ risk. (15054874)
2004
20
Proliferative lesions of the breast: carcinoma in situ. (15022899)
2003
21
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. (14659121)
2003
22
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. (12611452)
2003
23
Oral contraceptives and the risk of ductal breast carcinoma in situ. (14572155)
2003
24
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. (12670886)
2003
25
Lifetime recreational exercise activity and risk of breast carcinoma in situ. (14601085)
2003
26
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. (12118344)
2002
27
Breast carcinoma in situ: risk factors and screening patterns. (11734598)
2001
28
p53 mutations and expression in breast carcinoma in situ. (10623666)
2000
29
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. (9622698)
1998
30
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. (9071907)
1997
31
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. (8692711)
1996
32
Biological heterogeneity of breast carcinoma in situ. (8651598)
1996
33
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. (7654052)
1995
34
Breast carcinoma in situ. (20169700)
1992
35
Breast carcinoma-in-situ: an emerging problem in Singapore. (1329232)
1992
36
Receptors for estrogen and progesterone in breast carcinoma in situ. (1295456)
1992
37
Ten-year follow-up of breast carcinoma in situ in Connecticut. (1365682)
1992
38
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. (1677296)
1991
39
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. (1657650)
1991
40
Breast carcinoma in situ. (2535929)
1989
41
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. (2990246)
1985

Variations for Breast Carcinoma in Situ

About this section

Cosmic variations for Breast Carcinoma in Situ:

7 (show top 50)    (show all 79)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
110662TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
210867TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
310726TP53breast,NS,carcinoma,lobular carcinoma3
410728TP53breast,NS,carcinoma,lobular carcinoma3
510722TP53breast,NS,carcinoma,lobular carcinoma3
610725TP53breast,NS,carcinoma,lobular carcinoma3
744901TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
810648TP53breast,NS,carcinoma,lobular carcinoma3
911196TP53breast,NS,carcinoma,lobular carcinoma3
1011552TP53breast,NS,carcinoma,lobular carcinoma3
1143714TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1244737TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1310701TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1410779TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1543814TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
166932TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1744415TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1843606TP53breast,NS,carcinoma,lobular carcinoma3
1910660TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
2010656TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
2111089TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
2243559TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
2310768TP53breast,NS,carcinoma,lobular carcinoma3
24144210TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
2543695TP53breast,NS,carcinoma,lobular carcinoma3
26757PIK3CAbreast,NS,carcinoma,lobular carcinoma3
271191159PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
2827541PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
2929328PIK3CAbreast,NS,carcinoma,lobular carcinoma3
3029326PIK3CAbreast,NS,hyperplasia,atypical ductal hyperplasia3
31762PIK3CAbreast,NS,carcinoma,lobular carcinoma3
32754PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
33776PIK3CAbreast,NS,carcinoma,lobular carcinoma3
34764PIK3CAbreast,NS,carcinoma,lobular carcinoma3
3512592PIK3CAbreast,NS,carcinoma,lobular carcinoma3
3629329PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
3729325PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
38746PIK3CAbreast,NS,carcinoma,lobular carcinoma3
39775PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
40760PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
4130744PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
42763PIK3CAbreast,NS,carcinoma,lobular carcinoma3
4319778CDH1breast,NS,carcinoma in situ,lobular carcinoma in situ3
4419783CDH1breast,NS,carcinoma in situ,lobular carcinoma in situ3
4519516CDH1breast,NS,carcinoma in situ,lobular carcinoma in situ3
4620783CDH1breast,NS,carcinoma,lobular carcinoma3
4719786CDH1breast,NS,carcinoma in situ,ductal carcinoma in situ3
4819777CDH1breast,NS,carcinoma in situ,lobular carcinoma in situ3
4948358ERBB2breast,NS,carcinoma,lobular carcinoma3
5014065ERBB2breast,NS,carcinoma,lobular carcinoma3

Expression for genes affiliated with Breast Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

About this section

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 46)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.9CYP19A1, ESR1
2
Show member pathways
9.8BRCA1, BRCA2, TP53
39.8BRCA1, BRCA2, TP53
49.7ERBB2, TP53, VEGFA
5
Show member pathways
9.7CYP19A1, STS, SULT1E1
6
Show member pathways
9.7CYP19A1, STS, SULT1E1
79.7CYP19A1, STS, SULT1E1
89.6ERBB2, FGFR1, MET
9
Show member pathways
9.5BRCA2, ERBB2, TP53, VEGFA
109.4FGFR1, IL6, MET
119.4KDR, TP53, VEGFA
129.4ERBB2, FGFR1, MET, TP53
139.3FGFR1, KDR, VEGFA
14
Show member pathways
9.3FLT4, KDR, VEGFA
15
VEGF Pathway (Tocris)
Show member pathways
9.3FLT4, KDR, VEGFA
16
Angiogenesis (CST)
Show member pathways
9.3FLT4, KDR, VEGFA
179.2BRCA1, ERBB2, MET, TP53, VEGFA
18
Show member pathways
9.1CYP19A1, SRD5A1, STS, SULT1E1
199.1ESR1, KRT19, TP53
209.0IL6, LIF, MET, TP53
21
Show member pathways
9.0BRCA1, ESR1, KDR, VEGFA
229.0FGFR1, FLT4, KDR, VEGFA
23
Show member pathways
9.0FGFR1, FLT4, KDR, VEGFA
249.0BRCA1, BRCA2, CYP19A1, ESR1, TP53, VEGFA
258.8IL6, KDR, MET, VEGFA
26
Show member pathways
8.8FGFR1, FLT4, KDR, MET, VEGFA
278.7ERBB2, FGFR1, FLT4, KDR, MET
288.6BRCA1, BRCA2, ERBB2, ESR1, FGFR1, TP53
29
Show member pathways
8.5ERBB2, ESR1, IL6, MET, TP53, VEGFA
30
Show member pathways
8.5FGFR1, FLT4, IL6, KDR, MET
31
Show member pathways
8.5ERBB2, FGFR1, FLT4, KDR, MET, TP53
328.5ERBB2, FGFR1, FLT4, KDR, MET, TP53
33
Show member pathways
8.5BRCA1, BRCA2, ERBB2, FGFR1, IL6, MET
348.4BRCA2, ERBB2, FGFR1, IL6, MET, TP53
35
Show member pathways
8.3FGFR1, FLT4, IL6, KDR, MET, TP53
36
Show member pathways
8.2FGFR1, FLT4, IL6, KDR, MET, VEGFA
37
Show member pathways
8.2ERBB2, FLT4, IL6, KDR, MET, VEGFA
387.8BRCA1, FGFR1, FLT4, IL6, KDR, MET
39
Show member pathways
7.7ERBB2, FGFR1, FLT4, IL6, KDR, LIF
407.6ERBB2, ESR1, FGFR1, IL6, KDR, MET
41
Show member pathways
7.5ERBB2, ESR1, FGFR1, FLT4, IL6, KDR
42
Show member pathways
7.5BRCA1, ERBB2, FGFR1, FLT4, IL6, KDR
43
Show member pathways
7.5ERBB2, FGFR1, FLT4, IL6, KDR, LIF
44
Show member pathways
7.2ERBB2, FGFR1, FLT4, IL6, KDR, LIF
45
Show member pathways
6.9BRCA1, BRCA2, ERBB2, ESR1, FGFR1, FLT4
46
Show member pathways
6.7BRCA1, ERBB2, ESR1, FGFR1, FLT4, IL6

GO Terms for genes affiliated with Breast Carcinoma in Situ

About this section

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 49)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of transcription from RNA polymerase II promoter in response to hypoxiaGO:006141910.7TP53, VEGFA
2regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingGO:006066510.7FGFR1, MET
3positive regulation of p38MAPK cascadeGO:190074510.6MET, VEGFA
4positive regulation of protein kinase C signalingGO:009003710.6FLT4, VEGFA
5positive regulation of phospholipase C activityGO:001086310.5ESR1, FGFR1
6lymphangiogenesisGO:000194610.5FLT4, VEGFA
7DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.5BRCA1, BRCA2, TP53
8chromosome breakageGO:003105210.5BRCA1, BRCA2, TP53
9lung vasculature developmentGO:006042610.5LIF, VEGFA
10chordate embryonic developmentGO:004300910.4BRCA1, BRCA2, FGFR1
11branching involved in salivary gland morphogenesisGO:006044510.3FGFR1, IL6
12regulation of hematopoietic progenitor cell differentiationGO:190153210.3KDR, VEGFA
13positive regulation of positive chemotaxisGO:005092710.3KDR, VEGFA
14surfactant homeostasisGO:004312910.3KDR, VEGFA
15regulation of endothelial cell differentiationGO:004560110.3KDR, VEGFA
16negative regulation of hormone secretionGO:004688810.2IL6, LIF
17lymph vessel developmentGO:000194510.2FLT4, KDR
18positive regulation of mesenchymal cell proliferationGO:000205310.0FGFR1, KDR, VEGFA
19vascular endothelial growth factor signaling pathwayGO:003808410.0FLT4, KDR, VEGFA
20positive regulation of MAP kinase activityGO:004340610.0ERBB2, FGFR1, VEGFA
21cellular response to vascular endothelial growth factor stimulusGO:003592410.0FLT4, KDR, VEGFA
22branching morphogenesis of an epithelial tubeGO:004875410.0KDR, MET, VEGFA
23cell maturationGO:004846910.0FGFR1, KDR, VEGFA
24positive regulation of endothelial cell migrationGO:00105959.9FLT4, KDR, VEGFA
25steroid metabolic processGO:00082029.8CYP19A1, SRD5A1, SULT1E1
26positive regulation of peptidyl-serine phosphorylationGO:00331389.8IL6, LIF, VEGFA
27positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.8ERBB2, FGFR1, KDR
28positive regulation of endothelial cell proliferationGO:00019389.7FLT4, KDR, VEGFA
29regulation of apoptotic processGO:00429819.6BRCA1, ESR1, IL6, TP53
30negative regulation of gene expressionGO:00106299.6ESR1, FGFR1, MET, PGR
31lung alveolus developmentGO:00482869.5KDR, LIF, PGR
32blood vessel morphogenesisGO:00485149.5FGFR1, FLT4, VEGFA
33positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.5IL6, LIF, TP53, VEGFA
34cell proliferationGO:00082839.5BRCA2, ERBB2, MET, TP53, VEGFA
35regulation of cell proliferationGO:00421279.5BRCA1, FGFR1, IL6, TP53
36positive regulation of protein phosphorylationGO:00019349.4ERBB2, FLT4, KDR, VEGFA
37positive regulation of epithelial cell proliferationGO:00506799.4ERBB2, IL6, KDR, VEGFA
38transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.3ERBB2, FLT4, KDR, MET
39lung developmentGO:00303249.2FGFR1, KDR, LIF, VEGFA
40protein autophosphorylationGO:00467779.1ERBB2, FGFR1, FLT4, KDR, MET
41response to estrogenGO:00436279.0BRCA1, ESR1, KRT19, STS
42positive regulation of ERK1 and ERK2 cascadeGO:00703748.9FLT4, IL6, KDR, VEGFA
43positive regulation of gene expressionGO:00106288.8BRCA1, IL6, LIF, TP53, VEGFA
44peptidyl-tyrosine phosphorylationGO:00181088.8ERBB2, FGFR1, FLT4, KDR, MET
45negative regulation of apoptotic processGO:00430668.6ERBB2, FLT4, IL6, KDR, TP53, VEGFA
46positive regulation of MAPK cascadeGO:00434108.5ERBB2, FGFR1, FLT4, IL6, KDR, LIF
47vascular endothelial growth factor receptor signaling pathwayGO:00480108.4ERBB2, FGFR1, FLT4, KDR, VEGFA
48positive regulation of transcription from RNA polymerase II promoterGO:00459447.8BRCA1, ESR1, IL6, LIF, MET, PGR
49positive regulation of cell proliferationGO:00082847.7ERBB2, FGFR1, FLT4, IL6, KDR, LIF

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1vascular endothelial growth factor-activated receptor activityGO:000502110.1FLT4, KDR
2receptor signaling protein tyrosine kinase activityGO:000471610.0ERBB2, KDR
3growth factor bindingGO:00198389.6ERBB2, FLT4, KDR
4protein phosphatase bindingGO:00199039.6ERBB2, FLT4, MET, TP53
5steroid bindingGO:00054969.6ESR1, PGR, SULT1E1
6transmembrane receptor protein tyrosine kinase activityGO:00047148.8ERBB2, FLT4, KDR, MET
7protein tyrosine kinase activityGO:00047138.7ERBB2, FGFR1, FLT4, KDR, MET
8protein kinase activityGO:00046728.4ERBB2, FGFR1, FLT4, KDR, MET

Sources for Breast Carcinoma in Situ

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet